Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
AVXL Stock Chart & Stats
$3.64
-$1.39(-10.33%)
At close: 4:00 PM EST
$3.64
-$1.39(-10.33%)
Day’s Range― - ―
52-Week Range$2.86 - $14.25
Previous CloseN/A
Volume1.46M
Average Volume (3M)2.71M
Market Cap
$325.23M
Enterprise Value$661.88M
Total Cash (Recent Filing)$101.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Feb 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding89,348,110
10 Day Avg. Volume2,144,299
30 Day Avg. Volume2,711,488
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap2.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.47
Forecast
1Y Price Target
$20.00Price Target Upside449.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$221.71M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBlarcamesine shows significantly less cognitive decline in clinical trials compared to control groups, with treatment resulting in 77.4 weeks of time saved in disease progression for Alzheimer's patients.
Market PotentialBlarcamesine has favorable safety and tolerability characteristics, including the absence of serious adverse events, highlighting its potential for long-term therapeutic benefits in the Alzheimer's treatment market.
Regulatory ReevaluationAnavex Life Sciences has formally requested the European Medicines Agency to re-examine its opinion on blarcamesine in treating early Alzheimer's disease, offering a new evaluation by a different rapporteur and co-rapporteur.
Bears Say
Market SentimentThe short percentage of float has held steady at approximately 30% for over 6 months, indicating significant bearish sentiment in the market.
Regulatory ChallengesThe European Medicines Agency recently issued a negative opinion on the Marketing Authorisation Application for blarcamesine.
Uncertainty In ApprovalThe negative trend opinion has reduced the likelihood of a swift regulatory approval for blarcamesine.
Anavex Life Sciences News
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $2.86 and its highest was $14.25 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $325.23M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Feb 05, 2026 which is in 36 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Nov 25, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.12.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 89,348,110 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 12.338%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in AVXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (449.45% Upside)
$20.00 (449.45% Upside)
Blogger Sentiment
Neutral
AVXL Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.01%
12-Months-Change
Fundamentals
Return on Equity
-43.11%
Trailing 12-Months
Asset Growth
-23.42%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
AVXL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in clinical trials and strong financial positioning, contrasted by the setback of a negative CHMP opinion in Europe for blarcamesine and a decrease in R&D spending. Despite the challenges, the company remains optimistic about its scientific data and future regulatory discussions.View all AVXL earnings summariesAVXL Stock 12 Month Forecast
Average Price Target
$20.00
▲(449.45% Upside)
Technical Analysis
Galectin Therapeutics
―
Rocket Pharmaceuticals
―
Cellectis SA
―
Autolus Therapeutics
―
PepGen Inc.
―
Ownership Overview
3.23% Insiders
7.87% Mutual Funds
4.37% Other Institutional Investors
72.35% Public Companies and
Individual Investors